title: Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT.
authors.forename: P
authors.initials: P
authors.lastname: Armand
authors.forename: M-M
authors.initials: MM
authors.lastname: Sainvil
authors.forename: H T
authors.initials: HT
authors.lastname: Kim
authors.forename: J
authors.initials: J
authors.lastname: Rhodes
authors.forename: C
authors.initials: C
authors.lastname: Cutler
authors.forename: V T
authors.initials: VT
authors.lastname: Ho
authors.forename: J
authors.initials: J
authors.lastname: Koreth
authors.forename: E P
authors.initials: EP
authors.lastname: Alyea
authors.forename: E J
authors.initials: EJ
authors.lastname: Neufeld
authors.forename: R Y
authors.initials: RY
authors.lastname: Kwong
authors.forename: R J
authors.initials: RJ
authors.lastname: Soiffer
authors.forename: J H
authors.initials: JH
authors.lastname: Antin
mesh_terms: D000328:Adult; D015913:Chelation Therapy / Q000009:adverse effects; D003676:Deferoxamine / Q000009:adverse effects / Q000627:therapeutic use; D016903:Drug Monitoring; D057239:Early Termination of Clinical Trials; D005240:Feasibility Studies; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D007262:Infusions, Intravenous; D055104:Infusions, Subcutaneous; D007502:Iron Chelating Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019190:Iron Overload / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000628:therapy*; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000009:adverse effects / Q000494:pharmacology*; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000628:therapy*; D010865:Pilot Projects; D019172:Transplantation Conditioning / Q000009:adverse effects; D014184:Transplantation, Homologous; D055815:Young Adult
chemical_list: D007502:Iron Chelating Agents; D019653:Myeloablative Agonists; D003676:Deferoxamine